DE69605531D1 - Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans - Google Patents

Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans

Info

Publication number
DE69605531D1
DE69605531D1 DE69605531T DE69605531T DE69605531D1 DE 69605531 D1 DE69605531 D1 DE 69605531D1 DE 69605531 T DE69605531 T DE 69605531T DE 69605531 T DE69605531 T DE 69605531T DE 69605531 D1 DE69605531 D1 DE 69605531D1
Authority
DE
Germany
Prior art keywords
treatment
medicine
arteriosclerosis obliterans
carnitine derivative
carnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69605531T
Other languages
English (en)
Other versions
DE69605531T2 (de
Inventor
Marco Corsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE69605531D1 publication Critical patent/DE69605531D1/de
Publication of DE69605531T2 publication Critical patent/DE69605531T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69605531T 1996-03-04 1996-03-04 Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans Expired - Lifetime DE69605531T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96830093A EP0793962B1 (de) 1996-03-04 1996-03-04 Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans

Publications (2)

Publication Number Publication Date
DE69605531D1 true DE69605531D1 (de) 2000-01-13
DE69605531T2 DE69605531T2 (de) 2000-05-31

Family

ID=8225823

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69605531T Expired - Lifetime DE69605531T2 (de) 1996-03-04 1996-03-04 Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans

Country Status (13)

Country Link
US (1) US5811457A (de)
EP (1) EP0793962B1 (de)
JP (1) JPH09323927A (de)
KR (1) KR100346883B1 (de)
AT (1) ATE187329T1 (de)
CA (1) CA2198833C (de)
DE (1) DE69605531T2 (de)
DK (1) DK0793962T3 (de)
ES (1) ES2141463T3 (de)
GR (1) GR3032903T3 (de)
PT (1) PT793962E (de)
TW (1) TW349863B (de)
ZA (1) ZA971808B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
JP2002529408A (ja) * 1998-11-11 2002-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ アポトーシスを誘導することができる薬剤の調製のためのプロピオニルｌ−カルニチンの使用
AU1258699A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
US20050159481A1 (en) * 2002-04-18 2005-07-21 Chugai Seiyaku Kabushiki Kaisha Medicinal composition for improving angiotension-regulating function of blood vessel endothelium
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006061341A1 (en) * 2004-12-10 2006-06-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease
US7560485B2 (en) * 2005-10-04 2009-07-14 Sigma-Tau Industrie Parmaceutiche Riunite S.P.A. Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training
EP2353596A1 (de) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Kombinationszusammensetzung mit L-Carnitin oder Proponyl-L-Carnitin als Wirkstoffe zur Vorbeugung oder Behandlung von chronischer Veneninsuffizienz
PT2582368T (pt) 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
WO2012069221A1 (en) 2010-11-22 2012-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of the leber optic
JP2013544857A (ja) 2010-12-09 2013-12-19 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 皮膚疾患の治療のための局所使用のための組成物
EP2783695A1 (de) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiologische Ergänzung oder Medikament zur ophthalmischen Verwendung mit L-Carnitin oder Alkanoyl-L-Carnitinen in Kombination mit Eledoisin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
KR100346883B1 (ko) 2003-01-06
ES2141463T3 (es) 2000-03-16
ZA971808B (en) 1998-07-31
JPH09323927A (ja) 1997-12-16
ATE187329T1 (de) 1999-12-15
CA2198833A1 (en) 1997-09-04
PT793962E (pt) 2000-05-31
CA2198833C (en) 2003-07-22
DE69605531T2 (de) 2000-05-31
US5811457A (en) 1998-09-22
MX9701294A (es) 1997-09-30
TW349863B (en) 1999-01-11
DK0793962T3 (da) 2000-05-22
EP0793962B1 (de) 1999-12-08
GR3032903T3 (en) 2000-07-31
EP0793962A1 (de) 1997-09-10
KR970064602A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
DE69605531D1 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE69831016D1 (de) System zur überwachung und behandlung von schlafstörungen mittels eines transtrachealen katheters
DE69204639T2 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
ATE122232T1 (de) Melatoninderivate und kombinationen mit antiestrogenen zur behandlung von brustkarzinoma.
NO975234L (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
DE68908145T2 (de) Verwendung von L-Carnitinderivaten zur Herstellung eines Arzneimittels zur therapeutischen Behandlung von peripheren Neuropathien.
NO944339D0 (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
DE9305147U1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69313261T2 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE69133298D1 (de) Verwendung von acetylierten Mannanderivaten zur Behandlung von chronischen Atemwegserkrankungen
DE69215191D1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz
DE60112802D1 (de) Verwendung von isovaleryl-l-carnitin zur herstellung eines arzneimittels zur vorbeugung und therapie von osteoporose
IT1240779B (it) Impiego di l-carnitina nel trattamento delle miopatie funzionali laringee.
NO934444D0 (no) Lyskilde for PDT-behandling av hudlidelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition